Breaking News Instant updates and real-time market news.

MYL

Mylan

$36.49

-1.39 (-3.67%)

14:25
10/17/16
10/17
14:25
10/17/16
14:25

Senator Blumenthal reaffirms request for DOJ to reject Mylan settlement

In a letter to Attorney General Loretta Lynch dated Oct. 14, Connecticut Senator Richard Blumenthal reaffirmed his prior request that the Department of Justice reject the settlement agreement regarding the possible misclassification of Mylan's EpiPen product for purposes of the Medicaid drug rebate program. Previously, on Oct. 7, Blumenthal released a statement in response to Mylan's $465M settlement, calling it "a shadow of what it should be - lacking real accountability for Mylan's apparent lawbreaking." Reference Link

  • 09

    Nov

  • 28

    Mar

MYL Mylan
$36.49

-1.39 (-3.67%)

10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

INN

Summit Hotel Properties

$15.46

0.1 (0.65%)

05:20
09/26/17
09/26
05:20
09/26/17
05:20
Upgrade
Summit Hotel Properties rating change  »

Summit Hotel Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DRE

Duke Realty

$29.28

0.17 (0.58%)

05:17
09/26/17
09/26
05:17
09/26/17
05:17
Downgrade
Duke Realty rating change  »

Duke Realty downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REXR

Rexford Industrial

$29.56

0.05 (0.17%)

05:15
09/26/17
09/26
05:15
09/26/17
05:15
Downgrade
Rexford Industrial rating change  »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCO

Taubman Centers

$50.00

0.86 (1.75%)

05:14
09/26/17
09/26
05:14
09/26/17
05:14
Downgrade
Taubman Centers rating change  »

Taubman Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 11

    Oct

KIM

Kimco Realty

$19.58

0.4 (2.09%)

05:11
09/26/17
09/26
05:11
09/26/17
05:11
Upgrade
Kimco Realty rating change  »

Kimco Realty upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

GGP

GGP

$20.75

0.25 (1.22%)

05:11
09/26/17
09/26
05:11
09/26/17
05:11
Upgrade
GGP rating change  »

GGP upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAC

Macerich

$54.16

1.44 (2.73%)

05:10
09/26/17
09/26
05:10
09/26/17
05:10
Upgrade
Macerich rating change  »

Macerich upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$81.23

-1.46 (-1.77%)

05:06
09/26/17
09/26
05:06
09/26/17
05:06
Initiation
Dycom initiated  »

Dycom initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

PNC

PNC Financial

$133.52

0.09 (0.07%)

, GS

Goldman Sachs

$230.26

-0.77 (-0.33%)

05:04
09/26/17
09/26
05:04
09/26/17
05:04
Downgrade
PNC Financial, Goldman Sachs, Wells Fargo, Morgan Stanley, JPMorgan rating change  »

PNC Financial downgraded…

PNC

PNC Financial

$133.52

0.09 (0.07%)

GS

Goldman Sachs

$230.26

-0.77 (-0.33%)

WFC

Wells Fargo

$54.03

-0.22 (-0.41%)

MS

Morgan Stanley

$47.74

-0.48 (-1.00%)

JPM

JPMorgan

$94.12

-0.71 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 12

    Oct

  • 13

    Oct

  • 13

    Oct

  • 17

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JPM

JPMorgan

$94.12

-0.71 (-0.75%)

05:01
09/26/17
09/26
05:01
09/26/17
05:01
Downgrade
JPMorgan rating change  »

JPMorgan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 12

    Oct

  • 22

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JWN

Nordstrom

$47.32

0.44 (0.94%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BMY

Bristol-Myers

$63.19

-0.17 (-0.27%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Bristol-Myers management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

MCO

Moody's

$138.78

0.75 (0.54%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Moody's management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

ALB

Albemarle

$128.89

-5.4 (-4.02%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Albemarle management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

AFSI

AmTrust

$12.98

-0.3 (-2.26%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
AmTrust management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

NEE

NextEra Energy

$146.82

0.46 (0.31%)

, AES

AES Corp.

$11.21

0.1 (0.90%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Wolfe Research to hold a conference »

Utilities & Power…

NEE

NextEra Energy

$146.82

0.46 (0.31%)

AES

AES Corp.

$11.21

0.1 (0.90%)

PEGI

Pattern Energy

$25.53

-0.37 (-1.43%)

LNT

Alliant Energy

$42.25

0.52 (1.25%)

AGR

Avangrid

$47.10

0.6 (1.29%)

PNW

Pinnacle West

$86.85

0.7 (0.81%)

ETR

Entergy

$77.76

1.01 (1.32%)

PEG

PSEG

$46.50

0.31 (0.67%)

AWK

American Water

$82.48

0.45 (0.55%)

CMS

CMS Energy

$47.10

0.63 (1.36%)

AEP

American Electric

$71.04

0.47 (0.67%)

D

Dominion

$78.02

0.98 (1.27%)

ED

Consolidated Edison

$82.24

0.65 (0.80%)

ES

Eversource

$61.47

0.76 (1.25%)

EIX

Edison International

$79.27

0.99 (1.26%)

DUK

Duke Energy

$85.14

0.89 (1.06%)

DTE

DTE Energy

$109.74

1.36 (1.25%)

FE

FirstEnergy

$31.11

0.22 (0.71%)

WEC

WEC Energy

$64.24

0.63 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 02

    Oct

  • 02

    Oct

  • 05

    Nov

  • 29

    Nov

DNOW

NOW Inc.

$13.26

0.27 (2.08%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

ALGT

Allegiant Travel

$133.95

3.85 (2.96%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Allegiant Travel management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XPER

Xperi

$24.70

-0.35 (-1.40%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Xperi management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

OZRK

Bank of the Ozarks

$45.90

0.34 (0.75%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Bank of the Ozarks management to meet with Piper Jaffray »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

04:55
09/26/17
09/26
04:55
09/26/17
04:55
General news
Consumer Confidence to be reported at 10:00 »

September Consumer…

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Citigroup to hold a forum »

Pan Asia Corporate Forum…

BGG

Briggs & Stratton

$22.93

0.24 (1.06%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Briggs & Stratton management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

PLUS

ePlus

$87.95

-0.65 (-0.73%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
ePlus management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

04:55
09/26/17
09/26
04:55
09/26/17
04:55
General news
Breaking General news story  »

Federal Reserve Chair…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.